Press Release: Oak enters battle against malaria

June 25, 2015

Fresh from PR Log: Oxnard, CA – Oxnard-based pharmaceutical start-up Oak Therapeutics successfully concluded the pre-clinical phase of its anti-malarial medication Artelutrine™. Artelutrine™ is a reformulation of a highly effective, WHO-recommended combination therapy of the active ingredients Artemether and Lumefantrine using Oak Therapeutics novel delivery system, oral dissolvable strips (ODS).

 

 

Please reload

Featured Posts

All of us at Oak Therapeutics are extremely proud to announce that we just concluded initial preclinical testing of our anti-malarial medication Artel...

OAK THERAPEUTICS SUCCESSFULLY CONCLUDES TRIAL OF MALARIA MEDICATION

June 17, 2015

1/1
Please reload

Recent Posts
Please reload

Archive
Please reload

Search By Tags
Please reload

Follow Us
  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square

Oak Therapeutics, Inc., 2029 Becker Drive, Lawrence, KS 66047, United States, Tel. +1-913-346-0990, Email: office@oaktherapeutics.com